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REVIEW
Abstract: The incidence of invasive fungal infections, especially those due to Aspergillus
spp. and Candida spp., continues to increase. Despite advances in medical practice, the
associated mortality from these infections continues to be substantial. The echinocandin
antifungals provide clinicians with another treatment option for serious fungal infections.
These agents possess a completely novel mechanism of action, are relatively well-tolerated,
and have a low potential for serious drug–drug interactions. At the present time, the
echinocandins are an option for the treatment of infections due Candida spp (such as esophageal
candidiasis, invasive candidiasis, and candidemia). In addition, caspofungin is a viable option
for the treatment of refractory aspergillosis. Although micafungin is not Food and Drug
Administration-approved for this indication, recent data suggests that it may also be effective.
Finally, caspofungin- or micafungin-containing combination therapy should be a consideration
for the treatment of severe infections due to Aspergillus spp. Although the echinocandins
share many common properties, data regarding their differences are emerging at a rapid pace.
Anidulafungin exhibits a unique pharmacokinetic profile, and limited cases have shown a
potential far activity in isolates with increased minimum inhibitory concentrations to
caspofungin and micafungin. Caspofungin appears to have a slightly higher incidence of side
effects and potential for drug–drug interactions. This, combined with some evidence of
decreasing susceptibility among some strains of Candida, may lessen its future utility. However,
one must take these findings in the context of substantially more data and use with caspofungin
compared with the other agents. Micafungin appears to be very similar to caspofungin, with
very few obvious differences between the two agents.
Keywords: echinocandins, caspofungin, anidulafungin, micafungin, pharmacokinetics,
antifungals
Introduction
Despite advances in medical practice, the incidence of invasive fungal infections has
increased over the past 2 decades, such that Candida species are now the 4th most
prevalent causative agent of nosocomial bloodstream infections (Wisplinghoff et al
2004), and infections caused by Aspergillus spp. are also increasing rapidly.
Chandrasekar et al (2001) reported a steady increase in the frequency of clinical
isolates of Aspergillus spp. from 1994 to 1999. Presumably, these trends are due to
an increasing population of patients at risk for fungal infections, including patients
with AIDS, solid organ and hematopoietic stem cell transplant recipients, and other
patients at risk for immunosuppression (Clark and Hajjen 2002).
Over the past 10 years, a shift has occurred in the species of Candida causing
bloodstream infections. According to national intensive care unit (ICU) data (from
the National Nosocomial Infections Surveillance [NNIS] system), the percentage of
fungal bloodstream isolates (BSI) due to C. albicans significantly decreased from
1989-1999, while the percentage of fungal BSI due to C. glabrata significantly
increased (Trick et al 2002). In a recent multicenter observational study, non-albicans
species constituted ~50% of bloodstream isolates, while C. glabrata was implicated
in 21% of adult bloodstream isolates (Clark and Hajjen 2002; Pappas et al 2003).
Despite the introduction of newer, more potent antifungal agents, mortality due
to fungal infections remains high. The attributable mortality due to nosocomial
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Candida bloodstream infections at one institution was not
significantly different, when compared in two studies
conducted 15 years apart (38% in 1983–1986 versus 49%
in 1997–2001) (Gudlaugsson et al 2003). Meanwhile,
mortality associated with invasive Aspergillus approaches
100% in some patient populations, including bone marrow
transplant recipients (Lin et al 2001; McNeil et al 2001).
Fortunately, there has been a recent surge in antifungal
drug development. Triazole agents with broad spectrums
of action have arrived (voriconazole) and several more are
in development. Some of these agents have expanded the
azole spectrum of action to include fungi of the class
Zygomycetes (posaconazole). The liposomal polyenes have
combined the efficacy of amphotericin B with a decreased
incidence and severity of side effects. Possibly most
importantly, compounds with a completely novel mechanism
of action have arrived, the echinocandins (caspofungin,
micafungin, and anidulafungin).
Pharmacology
Chemistry
The echinocandins are semisynthetic lipopeptides produced
via chemical modification of natural products of fungi:
caspofungin from pneumocandin B0 from Glarea lozoyensis,
micafungin from the hexapeptide FR901370 from
Coleophoma  empedra, and anidulafungin from
echinocandin B0 from A. nidulans, respectively (Carver
2004; Murdoch and Plosker 2004; Cancidas PI 2005).
Chemical structures of the currently Food and Drug
Administration (FDA)-approved echinocandins are
provided in Figure 1 (Boucher et al 2004). Echinocandins
are cyclic hexapeptides with N-linked acyl lipid side chains
and molecular weights of approximately 1200 (Abruzzo et
al 1997; Mikamo et al 2000). Early investigation revealed
that the position and conformation of this N-linked acyl side
chain is crucial to the antifungal activity of the
echinocandins. Interestingly, these fatty side chains were
also implicated as a cause of hemolysis in early echinocandin
compounds; subsequent modifications led to compounds
with potent antifungal activity without hemolytic effects
(Klein and Li 1999).
Mechanism of action of echinocandins
The echinocandins are concentration-dependent, non-
competitive inhibitors of 1,3-β- and 1,6-β-D-glucan
synthase, an enzyme complex composed of two subunits,
encoded by the genes FKS1 and FKS2. Glucan synthase is
involved in the synthesis of 1,3-β-D-glucan, a
polysaccharide composed of 3 helically-entwined polymers
of glucose. Despite substantial work to elucidate the precise
location where echinocandins bind to the glucan synthase
enzyme complex, this question remains unresolved. Glucan
is an essential carbohydrate component of all fungal cell
walls, comprising 30%–60% of the fungal cell wall in
Candida and Saccharomyces. Changes in the characteristics
of the cell wall can lead to osmotic instability and eventual
cell lysis. Importantly, human cells do not contain 1,3-β-D-
glucan, thus avoiding direct human cell toxicity (Klein and
Li 1999; Deresinski and Stevens 2003; Carver 2004; Stevens
et al 2006).
The proportion of the fungal cell wall composed of
glucan varies widely between different species of fungi. 1,3-
β-D-glucan is more predominant in the cell walls of Candida
and Aspergillus species (especially C. albicans and A.
fumigatus) than in yeast forms of dimorphic fungi. Likewise,
the cell walls of mycelial forms of Histoplasma capsulatum,
Blastomyces dermatitidis, and Paracoccidioides braziliensis
contain significant amounts of 1,3-β-D-glucan, while
zygomycetes lack this target component. However, these
characteristics do not always predict echinocandin activity.
For example, the cell wall of Cryptococcus neoformans
contains 1,3-β-D-glucan but the echinocandins demonstrate
little activity against this pathogen. This suggests that there
are likely additional (or alternate) components of the
mechanism of action of the echinocandins (Feldmesser et
al 2000; Maligie and Selitrennikoff 2005).
In vitro, caspofungin is fungicidal against C. albicans,
causing lysis of growing and metabolically active cells
(Bartizal et al 1997). However, its activity against
Aspergillus is more complex: although caspofungin does
not reduce the number of colony-forming units (CFU) of A.
fumigatus, it causes significant injury, and perhaps lysis, to
the hyphal tips of actively growing cells. It is postulated
that this may prevent the organism from spreading beyond
the initial site of infection. As such, caspofungin is
considered fungistatic against Aspergillus, (as are the azole
antifungals, although some in vitro work suggests that
voriconazole may be fungicidal as well) in contrast to
amphotericin B, which is fungicidal (Krishnan et al 2005).
The clinical significance of these in vitro differences is not
clear (Bowman et al 2002). However, a recent in vitro study
in which phagocytic cells were combined with micafungin
provides a potential (and logical) explanation for the
confusing lack of correlation between in vitro and in vivo
activity of echinocandins. In vitro combination ofTherapeutics and Clinical Risk Management 2007:3(1) 73
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micafungin and phagocytes results in greater inhibition of
A. fumigatus growth than either micafungin or various
phagocytes by themselves (Choi et al 2004). Another study
further demonstrated that pretreatment of
polymorphonuclear leukocytes (PMNs) with granulocyte-
macrophage colony-stimulating-factor (GM-CSF) increased
the efficacy of the drug–immune component combination,
resulting in synergy (Gil-Lamaignere et al 2004).
Biofilms often develop on prosthetic devices (eg,
catheters), and Candida species, especially C. albicans and
C. parapsilosis, are often implicated as causative agents.
Biofilms develop in three phases: an early phase in which
fungi attach to the surface of the device; an intermediate
phase where blastospores aggregate to produce an
extracellular matrix; and a maturation phase, during which
fungi are incorporated into the matrix (Cocuaud et al 2005).
In 96-well biofilm models, echinocandins, unlike azoles,
appear to have potent activity against preformed Candida-
related biofilms. In addition, caspofungin prevents
adherence of C. albicans to epithelial cells, inhibiting the
early phase of development (Bachmann, VandeWalle, et al
2002; Soustre et al 2004). In silicone elastomer models of
biofilm infection, caspofungin and micafungin are effective
in killing C. albicans and C. parapsilosis biofilm cells
(sometimes >99% of cells, even at concentrations achieved
in vivo). Only amphotericin B lipid complex and liposomal
amphotericin B express similar activity (Kuhn et al 2002).
Interestingly, in the 96-well biofilm model, no evidence of
synergy or additive effects were observed when fluconazole,
amphotericin B, and caspofungin were used in combination
against C. albicans biofilms (Bachmann et al 2003). These
are important developments, since biofilm-related infection
and colonization are very difficult to eradicate with azole
antifungal therapy. Often, removal of the infected device is
required (Ramage et al 2002). However, whether these in
vitro models of biofilm infection are applicable to the clinical
Figure 1 Structures of echinocandins. Copyright © 2004. Reproduced with permission from Boucher HW, Groll AH, Chiou CC, et al. 2004. Newer systemic
antifungal agents: pharmacokinetics, safety and efficacy. Drugs, 64:1997-2020.Therapeutics and Clinical Risk Management 2007:3(1) 74
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setting is unknown, but merit further investigation for the
therapy of biofilm-associated infections.
Spectrum of activity
Comparison of in vitro activity of
echinocandins
Minimum inhibitory concentration (MIC) values should be
interpreted cautiously as standardized methods to test the
susceptibility of echinocandins have yet to be developed.
Interpretive breakpoints, which help guide the clinician to
make a correlation between in vitro susceptibility and in
vivo outcomes, are not yet available and will require
validation in clinical trials (Carver 2004). In vitro MIC
studies with echinocandins have employed multiple
methodologies, including differing inoculae, composition
and pH of media, reading times (24 vs 48 hours),
determination of MIC (“prominent” vs 80% or 90%
inhibition of growth), and growth forms (yeast vs mycelium
form). Kurtz and colleagues (1994) proposed the use of the
minimum effective concentration (MEC) as a new endpoint
of morphologic change for testing of caspofungin and other
echinocandins. The MEC is defined as the lowest
concentration of drug that cases the formation of
microcolonies of the organism, or the lowest concentration
at which a prominent decrease in turbidity occurs compared
with the growth control (Kurtz et al 1994, Carver 2004)
As a class, the echinocandins demonstrate excellent
activity against Candida spp. All 3 agents display higher
MICs for C. parapsilosis, C. lusitaniae, and C.
guilliermondii compared with other Candida species
(Pfaller, Boyken, et al 2005; Pfaller et al 2006). However,
at this time, little correlation can be made between MICs
and clinical outcomes with the echinocandins. In fact, a
recent study showed that patients with Candida isolates
displaying higher MICs (>2 µg/mL) had superior clinical
outcomes compared with those with isolates displaying
MICs <1 µg/mL (Kartsonis, Killar, et al 2005). A study
which attempted to determine whether the in vitro MIC
discrepancies between different Candida species (with C.
albicans displaying significantly lower MICs than C.
parapsilosis and C. guilliermondii) translated to differences
in an in vivo murine kidney infection model found
conflicting results. The isolate of C. parapsilosis that
displayed the highest MIC to caspofungin responded in vivo
to the lowest dose (1 mg/kg/day). Conversely, the two
isolates with the lowest MICs only responded in vivo to the
highest dose (5 mg/kg/day). Predictably, however, the
overall reduction of fungal burden was 100-fold less in the
models infected with non-albicans isolates (Barchiesi et al
2006). The echinocandins demonstrate excellent in vitro
activity against Aspergillus spp. An interesting component
of the spectrum of the echinocandins is their in vitro activity
against Pneumocystis carinii (P. jerovici) (Ito et al 2000;
Anonymous 2003; Pacetti and Gelone 2003). Interestingly,
the echinocandins were originally developed in part because
of their efficacy against Pneumocystis (Anonymous 2003;
Denning 2003; Carver 2004). The echinocandins do not
possess activity against the zygomycetes, Fusarium solani,
Scedosporium prolificans,  Cryptococcus spp, or
Trichosporon spp. (Zaas and Alexander 2005). Although
caspofungin, like other echinocandins, has minimal in vitro
activity against the agents of mucormycosis when tested in
vitro by standard techniques, the accuracy of current in vitro
testing against molds remains unclear. R. oryzae expresses
the target enzyme for echinocandins, and in the murine
model of disseminated mucormycosis, caspofungin
displayed limited activity against R. oryzae and the
combination of caspofungin (1 mg/kg/day) plus
amphotericin B lipid complex (5 mg/kg/day) was synergistic
and resulted in significantly improved survival versus either
therapy used alone. Nevertheless, clinical experience with
echinocandins for these infections are limited (Spellberg et
al 2005). While the echinocandins display activity against
the mycelial forms of endemic fungi such as Histoplasma
spp., Blastomyces spp., and Coccidioides spp., they display
significantly higher MIC values against the yeast forms of
these organisms (Wiederhold, Graybill, et al 2005). Finally,
caspofungin was found to inhibit the growth (via 1,3-β-D-
glucan synthase inhibition) of several rare molds, including
Alternaria sp., Curvularia sp., Scedosporium apiospermum
and prolificans, Acremonium sp., Bipolaris sp., and
Trichoderma sp. (Kahn et al 2006).
Susceptibility breakpoints have not been determined for
the echinocandins. In general, the echinocardins display
MIC90 values (MIC required to inhibit growth of 90% of
organisms) of ≤2 µg/mL against Candida spp. A review by
Zaas and Alexander (2005) succinctly compares the MIC
values of the echinocandins, and illustrates that in general,
anidulafungin displays the lowest MIC values against most
Candida  spp., followed by micafungin and then
caspofungin.
Anidulafungin displays low MICs against strains of C.
parapsilosis with high MICs to caspofungin and micafungin
and limited cases have shown a potential for activity inTherapeutics and Clinical Risk Management 2007:3(1) 75
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isolates with increased MICs to caspofungin and micafungin
(Ghannoum et al 2005). In addition, recent data reveals that
isolates of C. glabrata with elevated MICs to caspofungin
(8 µg/mL to 64 µg/mL) still display low MICs to
anidulafungin (2 µg/mL to 4 µg/mL) (Wiederhold, Graybill,
et al 2005). These results are interesting, and suggest that
anidulafungin may be more potent against certain resistant
Candida isolates when compared with the other
echinocandins. However, these results must be corroborated
with clinical data due to the lack of correlation of MICs
with treatment outcomes. In addition, the presence of human
serum decreases the in vitro potency of all the echinocandins
and neutralizes the in vitro MIC superiority of micafungin
over caspofungin (Park et al 2006).
Resistance to echinocandins
Although spontaneous resistance of C. albicans to
echinocandins has been documented in vitro, the specific
mechanisms of resistance have not been fully elucidated
and prospective worldwide surveillance of clinical Candida
isolates has revealed no evidence of emerging caspofungin
resistance (Kurtz et al 1996; Pfaller et al 2006). The
molecular target of echinocandins is the FKS1 subunit of
glucan synthase; predictably, mutations to this site confer
varying degrees of resistance to the echinocandins (Douglas
et al 1997). Recently, in vitro analysis of spontaneous
mutants of C. albicans has implicated this mechanism as an
important determinant of resistance (Balashov et al 2006).
In addition, analysis of a C. albicans strain (MIC=8 mg/L)
in a patient with recurrent esophagitis revealed a single
amino acid substitution (serine-to-proline) at position 645
of the FKS1 gene (Miller et al 2006). However, Hakki and
colleagues (2006) recently published a case of C. krusei
endophthalmitis and oropharyngeal candidiasis in which the
isolate displayed reduced susceptibility to all three
echinocandins, and was not mediated by a mutation of FKS1.
In addition, recent analysis of C. albicans isolates with
reduced echinocandin susceptibility found that
overexpression of the RER1 (Regulator of Echinocandin
Resistance) gene conferred resistance through an unclear
pathway (Ketko et al 2006).
Converse to the echinocandins, azole antifungals block
synthesis of lanosterol demethylase, which is encoded by
ERG11. Alteration in this gene may confer decreased
susceptibility to azoles. Upregulation of multidrug efflux
pumps coded for by multidrug resistance (MDR) or Candida
drug resistance (CDR) genes may also confer decreased
azole activity. Theoretically, caspofungin activity should not
be affected by these mechanisms of azole resistance. Indeed,
Bachmann, Patterson, and colleagues (2002) demonstrated
that caspofungin was highly active against 32 isolates of
both fluconazole susceptible- and resistant-C. albicans,
including those possessing alterations of the ERG11 and/or
CDR/MDR genes. However, overexpression of CDR2 efflux
can result in increased MICs to echinocandins (Shuetzer-
Muehlbauer et al 2003). In C. glabrata, upregulation of
CDR1 pumps does not confer reduced susceptibility to
caspofungin (Katiyar et al 2005). Finally, Paderu and
colleagues (2004) have shown that a high-affinity, saturable,
facilitated-diffusion transporter mediates caspofungin entry
into C. albicans. Disruption of this system represents a
potential mechanism of resistance.
Resistance mechanisms have also been elucidated for
several other fungal organisms. Overexpression of Sbe2p,
a Golgi protein which is involved in cell wall construction,
may confer resistance to caspofungin in Saccharomyces
cerevisiae (Osherov et al 2002). In vitro resistance to A.
fumigatus has been documented, with one strain
demonstrating a target-site mutation which conferred low-
level resistance. Another strain, deemed resistant, in fact
demonstrated an “Eagle-like” effect (described below)
(Gardiner et al 2005). Finally, as mentioned previously,
echinocandins do not display in vitro or in vivo activity
against Cryptococcus neoformans. Maligie and colleagues
(2005) attempted to determine if the mechanism of this lack
of effect was due to 1,3-β-D-glucan synthase resistance to
echinocandins. Surprisingly, the authors found that the
synthase enzyme was sensitive to caspofungin, although less
so than for C. albicans. As such, the mechanism of
Cryptococcus neoformans resistance to echinocandins is still
unknown (Maligie and Selitrennikoff 2005).
Several case reports have documented echinocandin-
resistant Candida spp. in the clinical setting. An AIDS
patient with thrush and esophagitis (due to C. albicans)
refractory to therapy with fluconazole and amphotericin B
lipid complex initially responded to caspofungin
monotherapy, but when therapy was discontinued, the
infection returned. Subsequent therapy with caspofungin
eventually failed. Serial isolates demonstrated caspofungin
MICs of 0.25 mg/mL and >64 mg/mL in the first and final
isolates, respectively. Although the utility of MIC values
with caspofungin have been questioned, this case
nevertheless presents an intriguing picture (Hernandez et
al 2004). In a second case, a patient with prosthetic valve
endocarditis due to C. parapsilosis was initially treated with
amphotericin B (0.7 mg/kg/day) + flucytosine for 7 days;Therapeutics and Clinical Risk Management 2007:3(1) 76
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therapy was then changed to caspofungin + intravenous
fluconazole. The initial fungal isolate displayed low MICs
to caspofungin and anidulafungin (2 µg/mL and 1 µg/mL,
respectively), but a high MIC (8 mg/mL) to micafungin.
After 6 weeks of therapy and sterile blood cultures, the
patient was discharged on chronic, suppressive therapy with
oral fluconazole. The patient was re-admitted 3 months later
with C. parapsilosis which was resistant to fluconazole and
voriconazole, had high MICs to caspofungin and micafungin
(>16 mg/mL), yet retained activity to anidulafungin and
amphotericin B. This case raises many questions about
echinocandin resistance that remain unanswered. Especially
intriguing is whether resistance to certain echinocandins
confer cross-resistance to others or to the entire class, and
whether azole resistance is mediated via mechanisms that
may result in reduced susceptibility to echinocandins
(Moudgal et al 2005). In addition, this case, combined with
newer data, raises the question of whether anidulafungin
has superior activity against C. parapsilosis. In a recent
study, researchers examined several caspofungin-resistant
isolates of C. parapsilosis from patients in a burn unit. The
investigators found that certain isolates displayed MICs of
64 µg/mL to caspofungin and micafungin, yet displayed
MICs of 1–2 µg/mL to anidulafungin. In addition, treatment
with caspofungin did not affect the cellular structure, while
treatment with anidulafungin caused cell lysis (Ghannoum
et al 2005).
Finally, an interesting “Eagle-like” effect has been
observed in vitro with caspofungin, whereby higher drug
concentrations do not result in a greater degree of killing
when compared with lower drug concentrations. When
exposed to therapeutic concentrations of caspofungin,
growth of C. albicans ceases. Paradoxically, exposure to
supratherapeutic concentrations of caspofungin results in
significant growth. This can occur either dramatically, in
which the number of colonies is too numerous to count, or
more subtly, where seemingly only a small number of cells
are able to survive (the so-called “mini-paradoxical effect”).
However, increasing the concentration even further results
in cessation of growth, suggesting that the resistance can
eventually be overcome. Investigators hypothesize that the
phenomenon may be due to selection of derepressed
resistance mechanisms, which require high concentrations
of drug to “turn-on.” Interestingly, when isolates which
illustrated this effect with caspofungin were tested against
micafungin and anidulafungin, the “Eagle-like” effect was
not observed (Stevens et al 2004, 2005). Subsequent studies
support the hypothesis that when C. albicans is exposed to
high caspofungin concentrations, genes encoding chitin, a
key cell wall polymer which is not targeted by caspofungin,
are rapidly and transiently induced to compensate for the
decreased synthesis of β-1,3- and β-1,6-glucan.
Interestingly, it appears that the presence of a calcineurin
inhibitor such as cyclosporine, inhibits this effect
(Wiederhold, Kontoyiannis, et al 2005; Stevens et al 2006).
In in vivo models, the “Eagle-like” effect was observed
in a rabbit model of invasive pulmonary aspergillosis, where
caspofungin doses ≥3 mg/kg/day were associated with
poorer survival (Petraitiene et al 2002). In a murine model
of invasive pulmonary aspergillosis, a concentration-
dependent reduction in mean pulmonary fungal burden was
observed following single intraperitoneal doses of
caspofungin of 0.25 mg/kg, 1.0 mg/kg, and 4.0 mg/kg. When
mice were treated for 96 hours with the same dosages
fractionated into 3 different dosing intervals (every 6, 24,
or 48 hours), a concentration-dependent reduction in mean
pulmonary fungal burden was observed in the 1mg/kg
dosage-fractionation group, with significantly lower mean
pulmonary fungal burden in mice dosed every 48 hours
versus every 6 hours. However, a paradoxical increase in
pulmonary fungal burden was observed in the highest
dosage-fractionation group (Wiederhold et al 2004).
However, recent studies offer conflicting results. Addition
of mouse serum to an in vitro model eliminated the
paradoxical effect (Abruzzo et al 2005). In a study assessing
whether the in vitro effect observed with several isolates
could be duplicated in an in vivo mouse model, no
paradoxical effect was observed following administration
of doses ranging from 0.01 mg/kg to 20 mg/kg, no
paradoxical effect was observed. However, a type of “cap
effect” was seen in certain isolates, whereby increasing the
dose higher than 0.5 mg/kg did not result in increased killing
(Clemons et al 2006).
At this time, many questions remain regarding the
mechanisms of resistance to the echinocandin antifungals.
Fortunately, the echinocandins have proven to be worthy
options in the treatment of azole-resistant Candida infections
(further highlighted in clinical studies presented below), and
clinical resistance remains a rare occurrence. However,
clinical examples do raise interesting questions regarding
cross-resistance among the echinocandins, and the potential
role of anidulafungin in resistant isolates. Again, however,
it is important to stress that differences based on
echinocandin MICs should be interpreted with caution.
Finally, it is unknown whether the interesting “Eagle-like”
effect observed in some in vitro models translates into aTherapeutics and Clinical Risk Management 2007:3(1) 77
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meaningful clinical effect as human studies have not been
performed. However, supratherapeutic plasma
concentrations utilized in in vitro studies have been observed
in pharmacokinetic studies in healthy volunteers, and may
be expected to occur in patients if larger doses of
echinocandins are employed in future studies.
Pharmacokinetics of echinocandins
As a class, the echinocandins possess many pharmacokinetic
similarities, including low oral bioavailability, high protein
binding, and relatively low CSF and urine concentrations
of parent drug (Table 1). Since urine concentrations of
echinocandins (or active metabolites) are minimal, their
clinical utility in treating urinary infections may be poor.
One study reviewed the response of 12 patients with
Candida urinary tract infections enrolled in 2 caspofungin
trials. The number of patients who responded favorably (11/
12) appears impressive. However, the limitations of the study
(retrospective, small patient numbers), compounded by the
difficulty in assessing true drug effect (since many fungal
urinary tract infections resolve without therapy), limit the
clinical utility of this data (Kartsonis et al 2003). All
echinocandins display linear pharmacokinetics following
administration of intravenous dosages, and are degraded
primarily by the liver (also in the adrenals and spleen) by
hydrolysis and N-acetylation (Denning 2003). Following
initial distribution, echinocandins are taken up by red blood
cells (micafungin) and the liver (caspofungin and
micafungin) where they undergo slow degradation to mainly
inactive metabolites, although two uncommon metabolites
of micafungin possess antifungal activity. Degradation
products are excreted slowly over many days, primarily via
the bile (Denning 2003). Fecal recovery data with
radiolabeled micafungin in healthy subjects, demonstrate
that approximately 40% of a 28mg dose is eliminated as
parent drug and metabolites in the bile. In an interesting
report of the successful treatment of a patient with candidal
cholangitis with caspofungin, the biliary concentration of
caspofungin was ~30% that of serum (Goicoechea et al
2004). This finding is not surprising considering the
evidence that caspofungin utilizes the OATP-1B1
transporter, which also transports bile, rifampin, and
cyclosporine (Sandhu et al 2005). Although it is not known
whether micafungin or anidulafungin also utilizes this
pathway, it appears unlikely since they interact less with
cyclosporine than does caspofungin (van Burik et al 2004;
Table 1 Pharmacokinetic parameters of echinocandins in adult subjects (Denning 2003; Deresinski and Stevens 2003; Wiederhold
and Lewis 2003; Carver 2004; Murdoch and Plosker 2004; Raasch 2004; Zaas and Alexander 2005)
Variable Caspofungin Micafungin Anidulafungin
Cmax (mg/L)(50 mg single dose) 7.64 4.95 2.07–3.5
Bioavailability 2%–7%
t1/2 (hours) 9-11  11-17 24–26
Vd (L/kg) 0.14 [9.67L] 0.215–0.242 0.5 [30–50L]
AUC (mg•h/L) 87.9–114.8 111.3 44.4–53
Protein binding (%) 96–97 99.8 84
Metabolism Via slow peptide hydrolysis Via catechol-O- Not metabolised; undergoes slow
and N-acetylation.  Also methyltransferase pathway chemical degradation to inactive
spontaneously degrades to metabolites
inactive product  
ClT (mL/min/kg) 0.15 0.185 0.26
fe  1.4 % 0.7% <1%
Elimination 35% feces, 41% urine 40% feces, <15% urine Primarily in feces (<10% as intact
(~1.4% as unchanged drug) drug), 1% urine
CSF penetration ? low ? low  < 0.1 %
(% of plasma)
Dosage adjustment in renal No significant changes in PK. No significant changes in PK. No change in PK observed.
insufficiency No dose adjustment needed. No dose adjustment needed. No dose adjustment needed.
Dosage adjustment in hepatic Child-Pugh 5–6: none Moderate dysfunction No dose adjustment needed 
insufficiency Child-Pugh 7–9: Significant (Child-Pugh 7–9): Cmax, Cl not
increase in AUC. Reduce significantly altered, AUC
maintenance dose to significantly decreased
35 mg/day compared with healthy
Child-Pugh >9: no data subjects.
Abbreviations: AUC, area under the plasma concentration-time curve; CI, confidence interval; ClT, total clearance; Cmax, maximum concentration; CSF, cerebrospinal
fluid; fe, fraction of drug excreted unchanged in the urine; PK, pharmacokinetic; t1/2, elimination half life; Vd, volume of distribution.Therapeutics and Clinical Risk Management 2007:3(1) 78
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Dowell et al 2005). None of the echinocandins serve as
substrates, inducers, or inhibitors of cytochrome P450
enzymes, or the P-glycoprotein transport system (Denning
2003).
Echinocandins are available only as parenteral
formulations, are not dialyzable, and do not require dosage
adjustment in patients with renal insufficiency. They have
minimal cerebrospinal fluid (CSF) penetration, largely due
to their high protein binding and large molecular weights,
although the clinical relevance of these findings may be
disputed, given that several other antifungal agents
(amphotericin B and itraconazole) are effective for the
treatment of fungal meningitis despite low CSF
concentrations (Denning 2003). However, one case report
documents failure of caspofungin in the treatment of
Candida endopthalmitis, presumably due to undetectable
intravitreous concentrations of caspofungin. The patient was
subsequently cured after therapy with 5 mg/kg/day
amphotericin B lipid complex (Gauthier et al 2005).
Interesting disparities do exist between the agents,
however. Among the echinocandins, anidulafungin is unique
in being eliminated almost exclusively by slow chemical
degradation rather than undergoing hepatic metabolism.
Anidulafungin has a lower maximum concentration (Cmax)
and degree of protein binding, and much longer half-life
and larger volume of distribution than the other two agents
(Raasch 2004).
Pharmacokinetics of echinocandins in
special populations
Renal insufficiency
As mentioned above, the echinocandins do not require
dosage adjustment in patients with renal insufficiency.
Hepatic insufficiency
The echinocandins have been studied in patients with
varying degrees of hepatic dysfunction. The area under the
concentration-time curve (AUC) of caspofungin is
significantly increased in patients with moderate (Child-
Pugh 7–9) hepatic insufficiency (Stone et al 2001; Cancidas
PI 2005). By contrast, the AUC of micafungin is decreased
in patients with moderate insufficiency; this is likely to be
due to an increased volume of distribution and lower protein
binding in these populations (Hebert, Smith, et al 2005;
Mycamine PI 2005). Anidulafungin concentrations were not
increased in subjects with mild (Child-Pugh 5–6), moderate,
or severe (Child-Pugh >9) hepatic insufficiency. Though a
slight decrease in AUC was observed in patients with severe
hepatic insufficiency, it was within the range of population
estimates noted for healthy subjects (Eraxis PI 2006).
Thus, it is suggested that the maintenance dose of
caspofungin be decreased from 50 mg to 35 mg daily in
patients with moderate hepatic insufficiency (Cancidas PI
2005). In patients receiving micafungin, dosage adjustments
are not recommended for patients with moderate hepatic
dysfunction (Mycamine PI 2005). Dosage adjustments are
not suggested for patients with mild, moderate, or severe
hepatic dysfunction who are receiving anidulafungin (Eraxis
PI 2006). Presently, as there is limited experience with
caspofungin and micafungin in patients with severe hepatic
insufficiency, recommendations for dosage adjustments
cannot be made at this time (Cancidas PI 2005; Mycamine
PI 2005).
Pediatrics
Caspofungin
Limited information is available regarding the use of
caspofungin in pediatric patients. The pharmacokinetics of
caspofungin in 39 children (2–11 years old) and adolescents
(12–17 years old) with neutropenia were compared with
those of adults who had received 50 mg or 70 mg daily for
mucosal candidiasis. After multiple doses, weight-based
dosing (1 mg/kg/day) in children (only two adolescents were
studied in the 1 mg/kg/day group) resulted in significantly
lower plasma concentrations compared with those achieved
in adults. However, in both children and adolescents, dosing
based on body surface area (50 mg/m2/day) resulted in an
area under the plasma concentration-time curve at steady
state (AUCss) similar to those achieved in adults receiving
50mg daily (Walsh et al 2005). In addition, a recent study
evaluating caspofungin therapy in 6 neonates with invasive
candidiasis revealed that doses of 2 mg/kg/day (or 25 mg/
m
2/day) resulted in similar plasma concentrations as those
in adults receiving 50 mg daily (Odio et al 2005).
Micafungin
In a Phase I, sequential group dose-escalation study in
pediatric patients, a 1.3- to 1.5-fold increase in the clearance
of micafungin was noted in patients 2–8 years of age. As
such, they recommended that a dosage of 1.5 times that of
the adult dosage be utilized in this population (Seibel et al
2005).
Anidulafungin
The pharmacokinetics of anidulafungin after daily doses
were investigated in immunocompromised pediatric (2–11
years) and adolescent (12–17 years) patients withTherapeutics and Clinical Risk Management 2007:3(1) 79
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neutropenia. Steady state plasma concentrations were
achieved on the first day after administration of the loading
dose (twice the maintenance dose). Cmax and AUCss
increased in a dose proportional manner. Concentrations and
exposures following administration of maintenance doses
of 0.75 mg/kg/day and 1.5 mg/kg/day were similar to those
observed in adults following maintenance doses of 50 mg/
day and 100 mg/day, respectively (Eraxis PI 2006).
Nursing mothers
Caspofungin, micafungin, and anidulafungin can be found
in the milk of lactating, drug-treated rats; it is not known
whether they are excreted in human milk. Caution should
be exercised when echinocandins are administered to a
nursing woman (Mycamine PI 2005; Cancidas PI 2005;
Eraxis PI 2006).
Pregnancy
The echinocandins are all categorized as Pregnancy
Category C. Anidulafungin and caspofungin cross the
placental barrier in rats and are detected in fetal plasma.
There are no adequate and well-controlled studies in
pregnant women; thus, echinocandins should be used only
if the potential benefit justifies the risk to the fetus
(Mycamine PI 2005; Cancidas PI 2005; Eraxis PI 2006).
Geriatric use
Dosage adjustments are not required for geriatric patients
receiving echinocandins (Mycamine PI 2005; Cancidas PI
2005; Eraxis PI 2006). In clinical studies of micafungin, a
total of 186 subjects were 65 years of age and older, and 41
subjects were 75 years of age and older. The exposure and
disposition of a 50mg micafungin dose administered as a
single 1 hour infusion to 10 healthy subjects aged 66–78
years were not significantly different from those in 10
healthy subjects aged 20–24 years. No overall differences
in safety or effectiveness were observed between these
subjects and younger subjects.
Plasma concentrations of caspofungin in healthy older
men and women (≥65 years of age) were increased slightly
(approximately 28% in AUC) compared with young healthy
men. A similar effect of age on pharmacokinetics was seen
in patients with candidemia or other Candida infections
(intra-abdominal abscesses, peritonitis, or pleural space
infections). No dose adjustment is recommended for the
elderly; however, greater sensitivity of some older
individuals cannot be ruled out.
In population pharmacokinetic analyses of
anidulafungin, the median clearance differed slightly
between the elderly group (patients ≥65, median clearance
(CL)=1.07 L/h) and the nonelderly group (patients <65,
median CL=1.22 L/h); however, the range of clearance was
similar.
Race and gender
The pharmacokinetics of echinocandins are similar among
Caucasians, Blacks, Asians, and Hispanics. Dosage
adjustments are not required based on race (Cancidas PI
2005; Mycamine PI 2005; Eraxis PI 2006).
Pharmacodynamics of echinocandins
The echinocandins exhibit concentration-dependent killing.
In a murine model of systemic candidiasis, the
pharmacodynamic parameter that predicted efficacy with
caspofungin was the ratio of the area under the curve to the
minimal inhibitory concentration (AUC/MIC) (Louie et al
2005). Caspofungin efficacy against C. albicans persists
even after serum concentrations fell below the MIC,
suggesting that caspofungin concentrations in tissues remain
high even after serum concentrations have declined (or that
caspofungin displays a significant post-antifungal effect)
(Louie et al 2005). In fact, a study utilizing time-kill
experiments found that when Candida is exposed to
caspofungin for only one hour (followed by drug washout),
virtually equivalent killing is achieved as when compared
with caspofungin exposure for 24 hours. In addition,
Candida growth is inhibited for at least 24 hours following
drug washout (Clancy et al 2006). In another animal model
with an experimental glucan synthase inhibitor, HMR 3270,
antifungal efficacy was predicted by the ratio of the Cmax to
the MIC (Cmax:MIC). A Cmax:MIC of 3 resulted in fungistatic
activity but fungicidal activity was not observed until the
Cmax:MIC ratio approached 10 (Andes et al 2003). In the
murine model of invasive pulmonary aspergillosis described
above (Wiederhold et al 2004), Cmax:MEC was the parameter
most closely associated with the reduction of pulmonary
fungal burden. Finally, the activity of anidulafungin against
C. albicans and glabrata in a neutropenic murine
disseminated candidiasis model was found to be greatest
when administered as large, infrequent doses (Andes and
Marchillo 2006).
Drug interactions with echinocandins
The echinocandins are not appreciable substrates, inhibitors,
or inducers of cytochrome P450, nor do they interact with
P-glycoprotein, as do some of the triazole antifungals.
Although micafungin is a substrate for and a weak inhibitor
of CYP3A in vitro, hydroxylation by CYP3A is not a majorTherapeutics and Clinical Risk Management 2007:3(1) 80
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pathway for micafungin metabolism in vivo. (Mycamine
PI 2005; Sakaeda et al 2005). As such, as a class,
echinocandins are expected to demonstrate a low capability
for producing drug–drug interactions. This has generally
proven true. No effect on cyclosporine metabolism was
noticed in vitro, and an in vivo study evaluating a potential
interaction between cyclosporine and anidulafungin
revealed only a clinically insignificant 22% increase in the
AUC of anidulafungin following 4 days of concomitant
cyclosporine therapy (Dowell et al 2005). Concurrent
administration of rifampin or a variety of other (204
substrates, 140 inhibitors, and 40 inducers of CYP450)
agents with anidulafungin does not affect the clearance of
anidulafungin (Dowell et al 2004).
Several studies have evaluated the interaction of
micafungin with various immunosuppressants. Although
micafungin does not significantly affect the clearance (or
AUC) of tacrolimus (Hebert, Blough, et al 2005), it increases
the AUC of sirolimus by 21% and decreases the clearance
of cyclosporine by 16% (Hebert, Townsend, et al 2005;
Mycamine PI 2005). This alteration in cyclosporine
clearance was deemed clinically insignificant by the
investigators. However, since 5 of 28 (18%) subjects in the
study experienced a clinically significant (>25%) change
in clearance, the authors suggested monitoring cyclosporine
levels during combination therapy with micafungin. The
package insert also states that micafungin increases the AUC
of nifedipine by 18%, entailing the need for close monitoring
of an increased effect of nifedipine (Mycamine PI 2005).
Predictably, the most data exists with caspofungin. One
group of authors hypothesized that since the metabolic
transformation of caspofungin is slow, perhaps the process
is limited by hepatocyte drug uptake transporters. Indeed,
several in vitro experiments demonstrated that the hepatic
transport protein OATP-1B1 may be responsible for hepatic
uptake of caspofungin (Sandhu et al 2005). Since
cyclosporine is a known substrate of this transporter, this
offers a possible (albeit unproven) explanation for its
interaction with caspofungin. Indeed, cyclosporine has been
shown to increase the AUC of caspofungin by ~35%
(Cancidas PI 2005). Similarly, rifampin (an inhibitor of
OATP-1), has been shown to both inhibit and induce
caspofungin metabolism. During the first day of rifampin
co-administration, a transient 61% increase in the AUC of
caspofungin is observed; however, when assessed after 14
days of rifampin administration, a 14%–31% reduction in
caspofungin troughs is observed. Therefore, the authors
recommend an increased dose of caspofungin during
concomitant administration with rifampin (Stone et al 2004).
A dosage increase is recommended in patients receiving
other enzyme inducers, such as efavirenz, nevirapine,
phenytoin, dexamethasone, and carbamazepine. Finally,
tacrolimus AUC, peak, and 12-hour concentrations are
decreased by approximately 20% during concomitant
administration with caspofungin, potentially necessitating
more frequent monitoring. The mechanism for this
interaction has not been elucidated (Cancidas PI 2005).
When reconstituting anidulafungin, 20% dehydrated
alcohol must be utilized (60 mL or 30 mL for 200 mg or
100 mg doses, respectively). This may be a concern for
several patient populations, such as those susceptible to
disulfuram reactions (for example, patients receiving
concurrent metronidazole use), or for patients who are
recovering alcoholics (Eraxis PI 2006).
Safety and adverse effects of
echinocandins
All three echinocandins are generally well-tolerated. The
most common adverse effects are listed in Table 2. While
there appear to be some differences between the agents, it
is important to keep in mind that caspofungin has been on
the market much longer than both micafungin and
anidulafungin. As such, it is difficult to derive conclusions
or make valid comparisons between available echinocandins
based on such small numbers of adverse effects. Finally,
limited experience suggests that caspofungin and
micafungin are safe to use in pediatric patients (Odio et al
2004; van Burik et al 2004; Groll et al 2005; Walsh et al
2005). The safety and effectiveness of anidulafungin in
pediatric patients has not been established (Eraxis PI 2006).
At the time of FDA approval, there were concerns
regarding the safety of caspofungin when combined with
cyclosporine. In initial studies utilizing a combination of
cyclosporine and caspofungin in 12 healthy volunteers, 5
experienced elevations in serum aminotransferase levels ≤3
times the upper limit of normal (ULN). In addition, 3 of 4
healthy subjects who received caspofungin 70 mg daily for
10 days plus two 3 mg/kg doses of cyclosporine on day 10
experienced transient increases in alanine transferase (ALT)
on day 11 that were <5 times the ULN. In the same study, 2
of 8 subjects who received caspofungin 35 mg daily for 3
days and two 3 mg/kg doses of cyclosporine on day 1
experienced increases in ALT<2 times ULN on day 2. As
such, the package insert recommended that liver function
tests be monitored closely when this combination is used
(Cancidas PI 2005).However, recent data suggests that thisTherapeutics and Clinical Risk Management 2007:3(1) 81
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interaction may be overstated. Three retrospective analyses
of the use of caspofungin and cyclosporine in patients do
not support a risk of clinically relevant hepatotoxicity (Marr,
Hachem et al 2004; Sanz-Rodriguez et al 2004; Glasmacher
et al 2006). A recent study further illustrates the lack of
clinical significance of caspofungin-immunosuppressant
interactions. Sixty-six patients from Phase II and III clinical
trials received caspofungin in combination with
cyclosporine (6 patients, for a mean of 14 days), tacrolimus
(58 patients, 21 days), sirolimus (3 patients, 12 days), and
mycophenolate (22 patients, 28 days). No patient on
cyclosporine developed increased transaminases or
discontinued therapy with caspofungin due to an adverse
event. Two patients receiving sirolimus experienced
transaminase elevations >2.5 times the ULN, and the
incidence of transaminase elevations in the caspofungin-
tacrolimus group was similar to the comparator agent
combination (amphotericin B plus tacrolimus) (Kartsonis,
Lipka, et al 2005).
One case report describes severe thrombocytopenia
associated with caspofungin use in a patient with multiple
aortic valve vegetations. The patient was receiving several
agents known to cause thrombocytopenia, including
piperacillin-tazobactam, heparin, 5-flucytosine, and
amphotericin B deoxycholate; however, the time course (and
subsequent rechallenges with several agents) were most
consistent with caspofungin. However, the authors do not
discuss the possible effects that the patient’s significant
disease processes and comorbidities may have had on
platelet counts. Nevertheless, the caspofungin package insert
cites the incidence of decreased platelet counts to be 3.1%
and 1.5% in patients receiving doses of 50 mg and 70 mg
daily, respectively (Lynch and Wong-Beringer 2004).
It appears from clinical trials that caspofungin may have
a higher propensity for causing histamine-induced reactions
compared with other echinocandins (Table 2). These
reactions may manifest as rash, facial swelling, pruritus,
facial swelling, sensation of warmth, and/or bronchospasm
(see http://www.cancidas.com/caspofungin_acetate/
cancidas/hcp/product_highlights/tolerability/index.jsp).
However, the package insert for micafungin states that
patients may experience more frequent histamine-mediated
Table 2 Adverse effects of echinocandins (Sable et al 2002; Carver 2004; Raasch 2004; Krause, Reinhardt, et al 2004; Cancidas PI
2005; Groll et al 2005; Mycamine PI 2005; Eraxis PI 2006)
Parameter Caspofungin Micafungin Anidulafungin
Hematologic Neutropenia 1.2% 1.0%
Leukopenia 0.9% 0.7%
Eosinophilia 3% Rarely related to
infusion
Thrombocytopenia <4%
Leukopenia <4%
Decreased Hgb, Hct 3%–12%
Gastrointestinal Nausea <3% 2.4% 1.0%
Diarrhea 2.1%
Vomiting <3% 0.7%
Dyspepsia 0.3%
Miscellaneous Hyperbilirubinemia 3.3%
Increased GGT <1%
Elevated AST/ALT Do not exceed 5X Rare, and generally <1%
ULN, transient, reversible. insignificant
~14%, <2%,
11%–24%
Hypokalemia 11% after 70 mg dose; 1.8% 2.4%–3.1%
<4% with 50 mg dose
Rash <1%
Pyrexia 12%–26%, 3.6% 0.7%
(depending on comparator)
Headache <3% 1.3%
Flushing <3%
Phlebitis/thrombophlebitis 3.5%, 12%–18% Rare 1.3%
Infusion related reactions/ 2% Rare 1 pt “flushing” with
Histamine release infusion
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutaryl transferase; Hct, hematocrit; Hgb, hemoglobin; pt, patient; ULN,
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reactions when the drug is infused more rapidly than 1 hour
(Micafungin PI 2005). Possible histamine-mediated
symptoms are infrequent when anidulafungin infusion rates
do not exceed 1.1 mg/minute. However, more experience
and comparative trials are needed to adequately assess the
relative incidence for each agent.
It appears that certain structural alterations in the core
molecule (ie, cyclic hexapeptides) of the echinocandins
influence their ability to influence histamine release.
Specifically, compounds with high proximal positive charge
density demonstrated a high histamine-releasing potency
when measured in mouse models with a histamine-
radioligand-immunoassay (Wang et al 2003). In vitro studies
in which human mononuclear, mast, and peripheral blood
cells were incubated with caspofungin demonstrated a
significant increase in histamine when incubated with
peripheral and mast cells. Likewise, the activity of histamine
N-methyltransferase, an enzyme which degrades histamine,
was reduced by 33% in peripheral blood. Anidulafungin
and micafungin were not studied in this in vitro system
(Cleary et al 2003).
Comparison of echinocandins by
indication
Clinical trials
Febrile neutropenia
Caspofungin
To date, only caspofungin has been studied for empiric
therapy in patients with febrile neutropenia; caspofungin
received FDA approval for this indication based on the
results of a noninferiority study in 1095 patients. These high-
risk patients (~60% in both groups had a primary diagnosis
of acute myelogenous leukemia) were randomized to receive
infusions of either caspofungin (70 mg loading dose,
followed by maintenance doses of 50 mg every 24 hours
for a median of about 10 days) or liposomal amphotericin
B (3.0 mg/kg of body weight). Of those receiving
caspofungin and amphotericin B, respectively, 190/556
(33.9%) and 180/539 (33.7%) patients had a favorable
response, defined as a composite score of 5 criteria:
successful treatment of baseline fungal infection; absence
of breakthrough fungal infection during therapy or within
7 days after the end of therapy; survival for 7 days after
discontinuation of therapy; resolution of fever; and no
premature discontinuation of drug due to lack of efficacy
or toxicity. Overall, outcomes with caspofungin therapy
were equivalent to therapy with liposomal amphotericin B.
However, secondary analysis suggested that therapy with
caspofungin therapy was significantly more successful than
liposomal amphotericin B in the treatment of baseline
infections: 14/27 (51.9%) versus 7/27 (25.9%), respectively,
and resulted in a higher proportion of patients surviving at
least 7 days. Liposomal amphotericin therapy was associated
with a significantly higher rate of adverse drug reactions,
including nephrotoxicity and infusion-related events (Walsh
et al 2004).
Prophylaxis in hematopoietic stem cell
transplantation and high-risk patient populations
The incidence of invasive fungal infections in patients
receiving hematopoietic stem cell transplantation (HSCT)
is between 14% and 25%; these infections are associated
with a high rate of mortality (Lin et al 2001; Wisplinghoff
et al 2004). Numerous studies have examined the utility of
antifungal agents in preventing invasive infection (Hamza
et al 2004). Although fluconazole is FDA-approved for this
indication, it lacks clinical activity against C. krusei and
Aspergillus spp. (Diflucan PI 2004). Potential advantages
of echinocandins versus fluconazole for this indication
include their expanded spectrum of activity against Candida
species and Aspergillus, and their decreased potential for
drug interactions. Potential disadvantages include their
higher cost, lack of oral formulations, and lack of activity
against emerging pathogens such as Scedosporium,
Fusarium, and zygomyces.
Caspofungin
Recently, caspofungin has been evaluated as prophylaxis
in patients with acute myelogenous leukemia or high-risk
myelodysplastic syndrome. Intravenous caspofungin (50 mg
daily) was compared with intravenous itraconazole (200 mg
twice daily X 2 days, then 200 mg once daily). Success of
therapy was defined as completion of prophylaxis (which
was continued until any of the following: absolute neutrophil
count >500 for 2 consecutive days; complete response;
death; change in leukemia therapy; unacceptable toxicity;
proven or probable invasive fungal infection; or 35 days of
prophylaxis) without development of invasive fungal
infection during the period of prophylaxis. The median
length of prophylaxis was 21 days in both groups.
Prophylaxis was effective in 44/86 (51%) of patients in the
itraconazole group and 55/106 (52%) in the caspofungin
group. Twelve patients developed invasive fungal infections:
5 in the itraconazole group (one patient with Aspergillus
pneumonia and four patients with candidemia- one due toTherapeutics and Clinical Risk Management 2007:3(1) 83
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C. krusei, one due to C. albicans, and two due to C. glabrata)
and 7 in the caspofungin group (2 patients with disseminated
Trichosporon infection, two with Aspergillus pneumonia,
one with Fusarium cellulitis, one with candidemia due to
C. parapsilosis, and one with both candidemia due to C.
albicans and C. glabrata and concurrent Aspergillus
pneumonia). Mortality was similar in both groups. This study
illustrates the disappointing efficacy of fungal prophylaxis
in high-risk patients and how prophylaxis may enable
organisms that are not susceptible to the prophylactic
antifungal agent to cause infection (Mattiuzzi et al 2006).
Micafungin
van Burik and colleagues (2004) evaluated 882 adult and
pediatric patients who had undergone allogeneic (for any
indication) or autologous (for hematological malignancy)
HSCT. Patients were randomized to receive infusions of
either micafungin 50 mg daily or intravenous fluconazole
400 mg daily until the earliest of the following: ≤5 days
after engraftment; day 42 after HSCT; the development of
proven, probable, or suspected invasive fungal infection;
the development of unacceptable drug toxicity; death; or
withdrawal or discontinuation from study participation.
Overall treatment success (defined as the absence of proven,
probable, or suspected fungal infection throughout the
period of prophylaxis, and through the end of a 4-week post-
treatment period) was 80% in the micafungin arm, and
73.5% in the fluconazole arm. Breakthrough infections
during prophylaxis included 1 case each of C. albicans, C.
parapsilosis, and C. lusitaniae during micafungin therapy;
following fluconazole therapy 1 case each of C. krusei and
C. parapsilosis were observed. There was 1 case of probable
aspergillosis and one case of fusariosis in the micafungin
treatment arm, and 7 cases (4 proven and 3 probable) of
aspergillosis among patients treated with fluconazole
(p=0.071). The only episode of zygomycosis occurred in a
patient treated with micafungin. Significantly fewer patients
in the micafungin arm 64/425 (15%) versus the fluconazole
arm 98/457 (21%) required empiric antifungal therapy.
Mortality was decreased, although not significantly, in the
micafungin arm (5.7% vs 4.2%, respectively). Based on this
limited data, micafungin may provide an option for
prophylaxis in patients undergoing HSCT (van Burik et al
2004).
The two available studies examining the efficacy of
echinocandins in preventing infections in high-risk patients
demonstrated remarkably different results. The micafungin
study included significantly more patients, and achieved
relatively high rates of successful outcomes (possibly due
to the extremely high-risk patient population in the
caspofungin group) compared with the caspofungin study.
As such, it is difficult to directly compare the two agents.
However, it does appear that both caspofungin and
micafungin would be acceptable options in the prophylaxis
of fungal infections in high-risk patients.
An important limitation of the study is that the duration
of prophylaxis was too short to evaluate efficacy in the late
post-engraftment period in allogeneic transplant recipients,
when this population is at often at increased risk for invasive
aspergillosis due to the use of corticosteroids, or the presence
of graft-versus-host disease (GVHD) or cytomegalovirus
(CMV) infection.
Invasive aspergillosis
Much of the data concerning the use of echinocandins in
invasive aspergillosis is derived from trials using
combinations of antifungal agents (discussed in more detail
below). However, both caspofungin and micafungin have
been studied as single-agent therapy in patients with invasive
aspergillosis.
Caspofungin
Maertens and colleagues (2004) evaluated the use of
intravenous caspofungin (administered as a 70 mg loading
dose on the first day, then 50 mg daily) in patients refractory
to (86%) or intolerant of (14%) previous antifungal therapy.
Response was determined by a panel of 3 experts in fungal
infections. A “complete response” was defined as resolution
of all signs, symptoms, and radiographic evidence of
aspergillosis, while a “partial response” was defined as
“clinically meaningful improvement” in the above
characteristics. Overall, 37/83 (45%) patients had a
favorable response (complete + partial). Of the patients
intolerant to previous therapy, 9/12 (75%) had a favorable
response, while 28/71 (39.4%) of those refractory to
previous therapy responded (1/3 were refractory to >1 drug).
In a second, compassionate-use study, caspofungin was
assessed in an additional 48 patients (of whom 3 were not
evaluated at the end of therapy) with aspergillosis refractory
to or intolerant of other therapy. An overall favorable
response (using the same criteria as the previous study) was
observed in 20/45 (44%) patients, with 9/45 (20%)
exhibiting a complete response to therapy. Of 10 patients
who received caspofungin in conjunction with another
antifungal agent, only 1 patient survived, highlighting the
severity of infection in these patients (Kartsonis, Saah, et al
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There are limited data assessing caspofungin as first-
line therapy in patients with proven (7/32 [22%]) or possible
(25/32 [78%]) aspergillosis. An overall response rate of 18/
32 (56%) was observed. Of the 18 responders, 12 (66%)
experienced complete and 6 (33%) partial responses. Twelve
of the 32 patients (38%) did not respond and 7 died of
mycotic infection. All patients who were neutropenic
received G-CSF therapy. Interestingly, 2/6 patients who did
not respond to caspofungin responded to voriconazole
therapy, and 6/6 of those with a partial or stable response to
caspofungin responded to voriconazole (Candoni et al 2005).
Additional case reports have corroborated the utility of
caspofungin in a diverse group of infections and patient
populations, including invasive fungal infections in
immunocompromised hosts (Taccone et al 2003; Carby et
al 2004; Ifran et al 2004). Several unique cases have shown
promising results: subcutaneously disseminated aspergillosis
in an allogeneic stem cell transplant patient, Aspergillus
brain abscess in a diabetic patient, cerebral aspergillosis
treated with amphotericin B deoxycholate plus caspofungin,
and 3 patients with endophthalmitis treated with
voriconazole + caspofungin (Chameuleau 2003; Colombo
and Rosas 2003; Breit et al 2005; Ehrmann et al 2005). There
have also been reports of treatment failures with
caspofungin. In one, a renal transplant patient treated with
voriconazole and caspofungin for pulmonary aspergillosis
developed infection due to Rhizopus oryzae, the patient
passed away after less than one week of treatment with
liposomal amphotericin B. In another case, an HSCT patient
who developed pulmonary aspergillosis failed long-term
treatment with varied combinations of liposomal
amphotericin B, itraconazole, and caspofungin, but resolved
following 7 months of voriconazole therapy (Blin et al 2004;
Eibl et al 2004).
Micafungin
Clinical data regarding the use of micafungin for the
treatment of aspergillosis is expanding. Administration of
intravenous micafungin 300 mg daily for 50 days was
successful in the treatment of pulmonary infection with A.
fumigatus in a patient with acute myeloid leukemia who
had required repeated and prolonged courses of intravenous
amphotericin B deoxycholate 1 mg/kg/day (Yokote et al
2004). In another case, a patient with acute lymphoblastic
leukemia complicated by invasive pulmonary aspergillosis
responded to 75–150 mg daily of intravenous micafungin.
The higher dose resulted in increased serum concentrations
of micafungin, and was associated with improvement in
signs and symptoms of infection (Ota et al 2004). A Phase
II study in Japan enrolled patients with presumed or
documented infection due to Aspergillus or Candida spp.
Patients received intravenous micafungin at doses of 25–
150 mg daily for 13–56 days. Response was defined as
improvement in radiologic findings without clinical
deterioration for invasive pulmonary aspergillosis (IPA); as
improvement in both parameters for patients with chronic
necrotizing pulmonary aspergillosis (CNPA); and as either
radiologic improvement without clinical decline, or clinical
improvement without radiologic decline, in patients with
pulmonary aspergilloma (PA). Overall, 24/41 (59%) patients
responded: 6/10 with IPA, 6/9 with CNPA, and 12/22 with
PA (Kohno et al 2004). In a recent, open-label,
noncomparative, international study in 225 adult and
pediatric patients (of whom 66 (29%) were neutropenic at
baseline) the use of intravenous micafungin was evaluated
in 29 (13%), as primary therapy, and in 192 (85%) patients
refractory to, or in 4 (2%) intolerant to previous antifungal
therapy. The dosage of micafungin was 75 mg/day initially
(1.5 mg/kg/day in patients ≤40 kg); the dosage was increased
in increments of 75 mg/day (1.5 mg/kg/day in patients
≤40 kg) if cultures remained positive, progression of disease
was evident, or no improvement was observed. Response
was determined by a panel of 3 experts in fungal infections.
The mean daily dose in adults was 111 mg/day (median
97 mg/day). The mean duration of treatment was 54 days.
Of 96 patients whose doses were not escalated, 30 (31%)
had a favorable response. Of 192 refractory patients, 148
(77%) had received a lipid preparation of amphotericin B,
86 (45%) amphotericin B deoxycholate, 66 (34%)
itraconazole, 7 (4%) caspofungin, 5 (3%) voriconazole, and
5 (3%) posaconazole. Combination therapy (micafungin
added to previous failing therapy) was utilized in 191
patients. Overall, 80 (36%) of patients had a favorable
(complete + partial) response; and additional 25 (11%) of
patients experienced stabilization of their infection. Of 29
patients who received micafungin as primary therapy, 11
had a favorable response (5/17 of those receiving
combination therapy and 6/12 of those receiving micafungin
alone). In the 34 patients receiving micafungin alone (18
refractory, 12 as primary therapy, and 4 due to prior drug
toxicity), 15 (44%) had a favorable response (Denning et al
2006). This study, very similar to the study by Maertens
and colleagues with caspofungin, suggests that micafungin
has clinical efficacy similar to that of caspofungin in the
treatment of invasive aspergillosis.Therapeutics and Clinical Risk Management 2007:3(1) 85
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Micafungin has also been studied in pediatric patients
(<16 years old) with proven or probable invasive
aspergillosis. In a noncomparative study, 58 patients (4
newly diagnosed, 54 refractory to prior therapy of whom
43% had undergone an allogeneic bone marrow transplant,
and 47% had undergone chemotherapy) with a mean age of
9 ± 4 years were treated with an initial dose of 1.5 mg/kg/
day of micafungin; 30 patients received further dose
escalation, and the mean treatment dose was 2.0 ± 1.2 mg/
kg/day. Only 2 patients received micafungin alone, while
the others received combination therapy with other
antifungals (the majority, 47, receiving liposomal
amphotericin B). Overall response (compete + partial) was
obtained in 26/58 (45%) patients. Of these, 9 (16%) had a
complete response, and 17 (29%) had a partial response. 5/
21 (24%) of those infected with A. fumigatus and 11/20
(55%) with A. flavus responded. These response rates are
similar to those of the trials described above, and as such,
micafungin (especially in combination) is an option for the
treatment of invasive aspergillosis in pediatric patients
(Flynn et al 2006).
Despite the available data encompassing very low
numbers of patients, the above studies are still significant
indicators of efficacy in a devastating disease. As evidence
of this, caspofungin received FDA approval for the treatment
invasive aspergillosis in patients who are refractory to or
intolerant of other therapies based solely on the results of
the Maertens study (83 patients!). The 2 studies evaluating
the use of echinocandins as first-line therapy for invasive
aspergillosis are interesting, and demonstrate similar
responses for caspofungin and micafungin. Possibly the
most urgent need for additional data is in clinical trials
examining the use of the echinocandins in the first-line or
combination therapy of invasive aspergillosis.
Esophageal candidiasis
Caspofungin and micafungin have been studied extensively,
and anidulafungin, less extensively, in patients with
esophageal candidiasis.
Caspofungin
Intravenous doses of caspofungin (35 mg, 50 mg, or 70 mg
daily) were compared with intravenous fluconazole 200mg
daily or amphotericin B 0.5 mg/kg/d for the treatment of
clinically or microbiologically fluconazole-resistant
Candida esophagitis. Of 31 patients, 14 (45%) were
refractory to fluconazole and 17 (55%) had fluconazole
MICs of ≥16 µg/mL. Overall, 7/11 (64%) of fluconazole-
refractory patients treated with caspofungin responded, and
11/14 patients (79%) whose Candida isolates had decreased
susceptibility to fluconazole (including 5/6 (83%) patients
with fluconazole MICs ≥64 µg/mL) treated with caspofungin
responded (Kartsonis et al 2002).
In a compassionate-use study with caspofungin in 21
patients with invasive mucosal candidiasis (17 esophageal,
4 oropharyngeal), 19 (91%) of whom had HIV disease and
were refractory to other therapy, 18/21 (86%) of patients
had a favorable response (Kartsonis et al 2004). A
subsequent study analyzed 120 patients with endoscopically
and microbiologically documented esophageal candidiasis
from 4 phase II/III caspofungin trials; C. albicans was
isolated in 109/110 of isolates, and was the sole isolate in
77%. Caspofungin (50 mg daily) was administered for a
median of 12 days in 120 patients. Symptoms resolved in
117/123 (95%) patients, within a median of 4 days. Response
rates were not significantly different for patients with CD4
counts greater than or less than 50 cells/mm3. However, 17%
of patients experienced relapse within 2 weeks of
discontinuation of therapy (Dinubile et al 2002).
Following these studies, in a randomized, double-blind
study comparing intravenous therapy with fluconazole
(200 mg daily) with caspofungin (50 mg daily) once daily
for 7 to 21 days, no significant difference in favorable
response rates (66/81 [81%] versus 80/94 [85%] patients,
respectively), were observed. Symptoms resolved by the
fifth day of treatment in the majority of patients. Relapse
was observed within 4 weeks following discontinuation of
therapy in 12/72 (17%) and 18/64 (28%) of patients
receiving fluconazole and caspofungin, respectively
(Villanueva et al 2002).
Intravenous therapy for 2 weeks with caspofungin (50mg
or 70 mg daily) was compared with amphotericin B
deoxycholate 0.5 mg/kg/day in 122 patients with
oropharyngeal or esophageal candidiasis, the majority of
whom were HIV-infected. Patients with possible fluconazole
resistance were excluded. The median time to symptom
resolution (4 days) was similar in all groups. Endoscopic
success was achieved in 74%, 89%, and 63% in patients
treated with caspofungin 50 mg, 70 mg, and amphotericin
B, respectively, at the 14-day post-treatment follow-up.
Significantly more adverse events occurred in the
amphotericin B arm, although only 1 was deemed serious.
Interestingly, the authors found no appreciable increases in
adverse events between the 2 doses of caspofungin which
showcases the future possibility of a valuable option of
increasing doses in non-responders without expectation ofTherapeutics and Clinical Risk Management 2007:3(1) 86
Eschenauer et al
a higher rate of side effects (Villanueva et al 2001). In a
similar study, intravenous caspofungin (35 mg, 50 mg, or
70 mg daily) or conventional amphotericin B (0.5 mg/kg of
body weight once daily) were administered for 7 to 14 days.
A modestly higher proportion of patients in each of the
caspofungin groups (74% to 91%) achieved favorable
responses compared with amphotericin B recipients (63%);
however, there was considerable overlap in the 95%
confidence intervals surrounding these point estimates
(Arathoon et al 2002).
Micafungin
Micafungin was studied in 120 South African patients with
HIV-related esophageal candidiasis: groups of 20 patients
were randomized to one of 6 dosing regimens (12.5 mg,
25 mg, 50 mg, 75 mg, or 100 mg per day). Clinical response
was found to be dose dependent: 6/18 (33.3%) of patients
in the 12.5 mg daily dosage group experienced clinical
clearing, compared with 18/19 (94.7%) of patients in the
100 mg daily dosage group. In addition, all patients at dose
schemes of 50 mg or greater exhibited endoscopic
improvement. Of concern, only 84 patients were included
in the per-protocol analysis, as 13 patients discontinued
therapy due to adverse events, and 16 patients were excluded
due to a negative histology or cytology, thus signifying a
lack of firm diagnosis. Despite this, most adverse events
were considered mild to moderate, consisting mostly of
gastrointestinal disturbances, liver function test
abnormalities, and rash (Pettengell 2004).
A double-blind, randomized, noninferiority study
compared response rates of micafungin (intravenous doses
of 50 mg, 100 mg, or 150 mg/daily) with intravenous
fluconazole (200 mg) for 14–21 days in 245 adult HIV-
positive patients. Once again, a dose-dependent response
was shown for micafungin, with a 69% documented cure in
the 50 mg arm and 90% cure in the 150 mg arm. Fluconazole
exhibited a 87% success rate. Based on these findings,
micafungin was determined to be noninferior to fluconazole
when administered at doses of 100 mg and 150 mg. 50% of
patients had improvement by 3 days of treatment, and 75%
were improved by day 7 (de Wet et al 2004).
Finally, a randomized, double-blind, noninferiority study
compared a minimum of 14 days of therapy with intravenous
micafungin 150 mg daily with intravenous fluconazole
200 mg daily. As expected, the majority of patients had a
diagnosis of HIV (94%), and C. albicans was most often
implicated as the cause of infection (98%). The mean number
of days on study medication was similar for both groups
(about 14 days), as were the rates of endoscopic cure (87.7%
for micafungin, 88.0% for fluconazole), and clinical success
(94.2% and 94.6%, respectively). Again, improvement was
often discernible within 3–5 days, and the rate of relapse
was higher, although not significantly so, in the micafungin
arm (15.2% vs 11.3% through week 4) (de Wet et al 2005).
In a recent multicenter, multinational, double-blind,
randomized, noninferiority study in 452 patients with
esophageal candidiasis, alternate day dosing of intravenous
300 mg of micafungin was as effective as daily intravenous
doses of either 150 mg of micafungin or 50 mg of
caspofungin (Buell et al 2005).
Anidulafungin
In a randomized, double-blind, noninferiority study in 601
patients, anidulafungin (100 mg intravenously on day 1
followed by 50 mg daily thereafter) was comparable to oral
fluconazole (200 mg on day 1, 100 mg daily thereafter) for
the treatment of esophageal candidiasis. The rates of
endoscopically-confirmed success were 98.8% and 97.2%
for fluconazole and anidulafungin, respectively. Of concern,
a 2-week follow-up revealed that only 64.4% of patients in
the anidulafungin group compared with 89.5% of patients
taking fluconazole had sustained success. This may have
been compounded, however, by the finding that more
patients took antiretrovirals during treatment in the
fluconazole arm (Krause, Simjee, et al 2004).
Summary
Based on currently available literature, there are no clear
distinctions between the echinocandins when used in the
treatment of esophageal candidiasis. All 3 agents have
proven noninferior to the current standard of care
(fluconazole), and all 3 carry a concern of significant relapse/
reinfection rates. In rabbits, poor penetration of
anidulafungin into saliva (although penetration into
esophageal tissue was quite high) has been demonstrated;
whether this is true for other echinocandins or in humans is
not known (Petraitis et al 2001). Until a comparative class
study is available, no clear distinction is evident based on
clinical efficacy.
Invasive candidiasis
Caspofungin
Caspofungin has been studied extensively in patients with
invasive candidiasis. Prior to its licensure, caspofungin was
evaluated in 16 patients with invasive candidiasis who were
refractory to or intolerant of other antifungal therapy: 8/16Therapeutics and Clinical Risk Management 2007:3(1) 87
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(50%) of the patients had acute leukemia/lymphoma, and
5/16 (31%) were diabetic. Sites of infection were
widespread, including four patients with chronic
disseminated disease. A favorable response was observed
in 13/15 patients (one patient died of staphylococcal sepsis
prior to evaluation) (Kartsonis, Killar, et al 2005). Following
this, a randomized, double-blind trial compared caspofungin
(50 mg daily) with amphotericin B deoxycholate (0.6–
0.7 mg/kg/day) in 239 patients with invasive candidiasis. A
successful outcome was achieved in 73.9% and 61.7% of
patients receiving caspofungin and amphotericin B,
respectively (95.6% Confidence Interval [CI]: -0.7 to 26.0);
response rates were consistent across most infection sources,
including 7 patients with Candida endophthalmitis.
Mortality was similar with either therapy (34.2% with
caspofungin, 30.4% with amphotericin B) (Mora-Duarte et
al 2002). These findings led to the subsequent FDA approval
of caspofungin for this indication.
Several case reports have highlighted the use of
intravenous caspofungin for uncommon or off-label
indications. One case documents resolution of non-albicans
Candida endocarditis without valve replacement, using a
70 mg loading dose followed by 50 mg daily for 6 weeks.
The only other antifungal agent the patient had received
was intravenous fluconazole for 4 days prior to initiation of
caspofungin (Rajendram et al 2005). In another case, a
patient with endocarditis due to C. guilliermondii was cured
with surgery and 6 weeks of caspofungin monotherapy
(50 mg daily) (Nevado et al 2005). These two cases present
an encouraging picture for the use of caspofungin, even as
monotherapy, for the treatment of fungal endocarditis. A
combination of liposomal amphotericin B and caspofungin
was successful in treating a case of Candida endocarditis
without valve replacement (Jimenez-Exposito et al 2004).
However, another patient with C. albicans endocarditis did
not respond to caspofungin monotherapy and surgery, and
developed likely fungal brain abscesses. The patient
subsequently improved on liposomal amphotericin B + oral
fluconazole therapy. This study highlighted concerns that
the poor central nervous system (CNS) penetration of
caspofungin might allow for dissemination of fungi to the
CNS (Prabhu and Orenstein 2004). However, in another
case report, a patient with C. albicans meningitis refractory
to amphotericin B (1 mg/kg/day), intravenous fluconazole
and intrathecal amphotericin B (1 ml of 0.25 mg/ml 3 times
per week) improved dramatically following caspofungin
monotherapy (Liu et al 2004). Finally, 2 case reports present
conflicting data concerning the use of caspofungin in the
treatment of Candida endophthalmitis. In one case, a patient
failing caspofungin monotherapy had undetectable
intravitreous concentrations of caspofungin; the patient was
subsequently cured after therapy with amphotericin B lipid
complex (5 mg/kg/day) (Gauthier et al 2005). However,
another patient was cured after a 28-day course of
caspofungin monotherapy (initially 50mg daily, later
decreased to 35 mg daily due to moderate hepatic
impairment). Intravitreous drug concentrations of
caspofungin were not obtained (Sarria et al 2005). These
case reports are interesting, but do not provide sufficient
data upon which to form decisive conclusions regarding the
use of caspofungin in endocarditis, meningitis, and
endopthalmitis.
There are limited data regarding the use of caspofungin
monotherapy in pediatric patients with invasive candidiasis.
Encouraging results were observed when caspofungin was
substituted for amphotericin B deoxycholate in 9 neonates
with persistent infection. All blood cultures were sterilized
within 3 to 7 days of initiating caspofungin, and in one case,
an atrial vegetation was eradicated (Odio et al 2004).
Another case report also documents a successful use of
caspofungin in a patient with amphotericin B- and
fluconazole- resistant Candida glabrata endocarditis
(Mrowczynski and Wojtalik 2004). Caspofungin has also
been added without serious side effects to failing regimens
in a variety of pediatric patients, including a low-birth-
weight neonate, several bone marrow transplant recipients,
and a 3-year old child with persistent candidemia, with
generally positive results (Franklin et al 2003; Hesseling
et al 2003; Castagnola et al 2004; Wertz and Pretzlaff
2004).
Micafungin
Data regarding the efficacy of micafungin for the treatment
of invasive candidiasis are emerging. An open-label study
in Japan documented a 100% response (6/6 patients) in the
treatment of candidemia. However, one patient with
disseminated candidiasis did not respond to treatment
(Kohno et al 2004). In an open-label, noncomparative trial
in 126 patients with candidemia, micafungin therapy
produced a complete or partial response in 83.3% of patients;
however, since dose escalation (with dosages up to 200 mg/
day) was allowed, and the majority of patients received
concurrent antifungal agents, the clinical applicability of
this trial is limited (Ostrosky-Zeichner et al 2005). A double-
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micafungin (100 mg daily) with liposomal amphotericin B
(3 mg/kg/day) for 2-4 weeks was undertaken in mainly non-
neutropenic (12.9% vs 10.5% of patients, respectively),
mostly candidemic (~85% in both arms) patients.
Micafungin treatment was considered effective (clinical plus
mycological response) in 89.6% of patients (181/202)
compared with 89.5% (170/190) in the amphotericin B
group. 62.4% and 58.9% of patients, respectively, were
infected with non-albicans Candida species. Both groups
were equal with regard to eradication of C. glabrata and C.
parapsilosis, and catheters were removed in an equal
frequency in both groups. The amphotericin B group had a
significantly higher incidence of side effects, including
infusion-related reactions and increases in serum creatinine.
As such, the investigators concluded that micafungin was
noninferior to amphotericin B, but displayed a significantly
more favorable side effect profile (Ruhnke et al 2005). A
randomized, 1:1:1, double blind, noninferiority trial
comparing 2 doses of micafungin (100 mg/day and 150 mg/
day) with caspofungin (70 mg loading dose, then 50 mg/
day) was recently presented in abstract form. The primary
efficacy endpoint was clinical and microbiological response
at the end of intravenous therapy, with a pre-specified margin
for noninferiority of -15%. 593 patients received at least
one dose of study drug, and the three groups had similar
baseline characteristics. Overall success was 73.9% for
micafungin 100 mg/day, 70.3% for micafungin 150mg/day,
and 71.4% for caspofungin. Based on these results,
micafungin was determined noninferior to caspofungin. In
addition, this study showed no advantage of micafungin at
150 mg/day compared with 100 mg/day. The safety profiles
for the 3 treatments were similar. Further analysis of
response stratified by organism are pending (Betts et al
2006).
Micafungin (2 mg/kg/day) was recently compared with
liposomal amphotericin B (3 mg/kg/day) for the treatment
of invasive candidiasis in pediatric patients (≤15 years old)
in a randomized, double-blind study. The study included
98 patients: the majority had candidemia (92% in the
micafungin group, 94% in the amphotericin B group), with
30 (63%) and 35 (70%) patients, respectively, infected with
non-albicans species. Overall treatment success (clinical and
mycological response) in the modified intention-to-treat
patients was similar for the two agents, 35/48 (72.9%) for
micafungin and 38/50 (76.0%) for amphotericin B. No
significant differences were found when responses were
analyzed according to patient age, neutropenic status, safety
profiles, or in 12-week survival. As such, micafungin may
be considered in pediatric patients with candidiasis,
especially those with candidemia (Arrieta et al 2006).
Anidulafungin
In a Phase II, dose-ranging study, 123 patients with invasive
candidiasis were randomized to 50 mg, 75 mg, or 100 mg
daily. Of the 68 evaluable patients (94% of which had
candidemia only), success rates were 84%, 90%, and 89%
in each group, respectively (Krause, Reinhardt, et al 2004).
Eradication rates were also dose-dependent (74%, 85%, and
89%, respectively). MICs for both C. albicans and non-
albicans isolates were similar, except for C. parapsilosis
isolates, which comprised 9.5% of isolates. The MIC range
(4–8 µg/mL) for this organism was significantly greater than
those of other isolates. However, as described above with
caspofungin, high MICs did not predict treatment failure: 6
of 7 infections due to isolates of C. parapsilosis with MICs
of 4–8 µg/mL were eradicated (Pfaller, Diekema, et al 2005).
Based on these results, a randomized, double-blind Phase
III trial compared intravenous anidulafungin (200 mg
loading dose X 1, then 100 mg daily) with intravenous
fluconazole (800 mg loading dose X 1, then 400 mg daily)
in 256 patients was conducted. Patients in either arm could
switch to oral fluconazole after 10 days. Approximately 3%
of patients were neutropenic, and 89% had only candidemia.
About 40% of isolates were of non-albicans spp. in both
arms. Treatment success required both a clinical and
microbiological response. A statistically significantly greater
response was found in the anidulafungin arm in the
microbiological intent-to-treat arm at the end of intravenous
therapy (75.6% vs 60.2%). At the same time point, 6.3% of
patients in the anidulafungin arm had persistence of
infection, compared with 14.4% in the fluconazole arm. A
secondary analysis at a two-week follow-up again revealed
statistical superiority in the anidulafungin arm (64.6% vs
49.2%), with similar results again at six weeks (55.9% vs
44.1%). A subset analysis revealed that anidulafungin
retained its statistical superiority only in patients with
APACHE II scores >20 (Reboli et al 2005).
Summary
At this time, the only distinction that can be drawn between
the echinocandin agents and their utility in invasive
candidiasis is that caspofungin and anidulafungin, to date,
are the only agents to have FDA approval. However, based
on limited information, micafungin also appears to be
effective. As such, it is difficult to discern the preferred
echinocandin for the treatment of invasive candidiasis.Therapeutics and Clinical Risk Management 2007:3(1) 89
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Studies which directly compare the agents would help
delineate any differences.
Combination therapy with echinocandins and
other antifungal agents
The unique mechanism of action of the echinocandins has
rekindled an interest in utilizing combination antifungal
chemotherapy. Most examples of additive or synergistic
effects make theoretical sense, such as flucytosine +
amphotericin B in cryptococcal meningitis and rifampin or
an aminoglycoside in combination with a β-lactam antibiotic
for selected bacteria. In the same way, an echinocandin in
combination with a polyene or azole antifungal makes
theoretical sense, given the different mechanisms of action.
However, a logical theory does not exclude the possibility
for antagonism when two agents are combined. The various
combinations have been tested against several fungi,
including Trichosporon asahii in a murine model (Serena
et al 2005), Scedosporium spp in vitro (Yustes and Guarro
2005), Cryptococcus spp. in vitro (Johnson et al 2004), and
Mucor in a successful patient case (Spellberg et al 2005).
Several extensive reviews have been published recently on
combination therapy for fungal infection (Lewis and
Kontoyiannis 2001; Johnson et al 2004; Baddley and Pappas
2005). The only randomized, blinded study evaluating the
efficacy of combination therapy involves fluconazole versus
fluconazole + amphotericin B deoxycholate for candidemia.
This study found a trend towards improved outcomes in the
combination therapy group (Rex et al 2003). However, at
the present, most interest concerning combination therapy
lies in the treatment of aspergillosis, given the continued
high mortality of these infections. The results of in vitro
and animal studies for the most relevant fungi are
summarized in Table 3.
Caspofungin
Several small series of patients have reported successful
treatment of refractory infections with combinations of
caspofungin and itraconazole, voriconazole, or lipid
preparations of amphotericin B. One study retrospectively
assessed the response of 48 patients with invasive
aspergillosis who received combination therapy with
liposomal amphotericin B and caspofungin in whom 17
(35%) had received combination therapy as initial therapy,
while an additional 31 (65%) patients had progressive
disease on liposomal amphotericin B alone. The overall
response rate was 42% (22% in patients with documented
infection, and 60% in those with possible infection). In those
patients whose disease had progressed on liposomal
amphotericin B monotherapy, the response rate was 18%
and 57%, respectively. 5/13 (38%) patients with neutropenia
persisting through the study period responded to
Table 3 Echinocandin-containing combination antifungal therapy (in vitro and animal data) (Johnson et al 2004)
Caspofungin Candida spp. In vitro combination with fluconazole yielded generally indifferent results, and
showed potential benefit in an animal study.
Aspergillus spp. In vitro and animal combination with AmB and triazoles generally synergistic.
Antagonism not seen. AmB + caspofungin + flucytosine shown to be synergistic
against all tested isolates in vitro (Dannaoui et al 2004). Sulfmethoxazole
combination synergistic in 29/31 isolates in vitro (Yekutiel et al 2004).
Mucormycosis Combination with AmB showed survival benefit in animal model (Spellberg et al
2005). 
Micafungin Aspergillus spp.  In in vitro and animal models, the combination of AmB and triazole antifungals was
generally synergistic, and significantly decreased the EC90 of voriconazole against A.
fumigatus and A. terreus, but not A. flavus (Heyn et al 2005; Lewis and Kontoyiannis
2005). 
Candida spp. Voriconazole combination indifferent in 97% of isolates, most likely due to already
 low MICs with micafungin (Heyn et al 2005). Combination with amphotericin B
required to eradicate C. glabrata infection in immunosuppressed mice (Olson et al
2005).
Scedosporium spp. and Combination with voriconazole syngergistic in 64% of isolates. Antagonism not
Fusarium solani noted (Heyn et al 2005). 
Anidulafungin Aspergillus spp.  In vitro combination with AmB was antagonistic in 5/26 strains. Combination with
itraconazole + voriconazole generally showed synergy (Philip et al 2005).
Candida spp.  In vitro combination with AmB, itraconazole, ketoconazole, itraconazole, and 5-
fluorocytosine generally showed additivity or indifference. Antagonism noted in all
strains of C. tropicalis with combination of ketoconazole and anidulafungin
(Karlowsky et al 2006).
Abbreviations: AmB, amphotericin B; EC90, effective concentration 90%.Therapeutics and Clinical Risk Management 2007:3(1) 90
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combination therapy (Kontoyiannis et al 2003). In a similar
study, which included 85 patients with progression of disease
despite 72 hours of appropriate therapy, 33 (39%) patients
demonstrated a complete or partial response. However, 13
patients received triple therapy (micafungin, amphotericin
B, and an azole) (Ratanatharathorn et al 2002). Investigators
from the University of Washington examined the outcomes
of 47 patients who failed amphotericin B formulations and
received voriconazole alone or in combination with
caspofungin. Compared with single-agent therapy,
combination therapy significantly improved 3-month
survival and reduced mortality (Marr, Boeckh, et al 2004).
Another study analyzed the efficacy of caspofungin
combined with polyene formulations (16 patients),
itraconazole (7), or voriconazole (30) in patients refractory
to (87%) or intolerant of (13%) prior therapy, of whom 7
(13%) patients had disseminated infection, and 43 (81%)
had pulmonary infections. The average duration of therapy
was 31 days (range 1–196), with only 10 patients (19%)
receiving therapy for <7 days. Efficacy, determined by an
independent expert assessment, was achieved in 29/55
patients (55%) at the end of combination therapy, and 25/
51 (49%) after 84 days of therapy. At the end of combination
therapy, efficacy was achieved in 18/30 (60%) in the
caspofungin–voriconazole group, compared with 3/7 (43%)
in the caspofungin–itraconazole arm and 8/16 (50%) in the
caspofungin–amphotericin B arm. Efficacy was similar in
patients refractory to prior therapy (54%) and in those
intolerant (57%), as well as in patients who were either
neutropenic or non-neutropenic at study outset (57% vs
52%, respectively) (Maertens et al 2005).
Singh and colleagues (2006) compared a historical
control group of 47 solid organ transplant recipients treated
as primary therapy for aspergillosis with liposomal
amphotericin B monotherapy from 1999–2002, to 40
patients treated from 2003–2005 with voriconazole plus
caspofungin (Singh et al 2006). 90-day mortality was
significantly lower in the combination therapy versus the
monotherapy group (51% vs 67.5%, respectively). In
addition, in transplant recipients with renal failure, and in
those with A. fumigatus infection, combination therapy was
independently associated with an improved 90-day survival.
As such, voriconazole + caspofungin may be preferred in
solid organ transplant patients with invasive aspergillosis
(Singh et al 2006). However, the results do not prove the
superiority of combination therapy, especially since a
previous randomized, controlled trial proved the superiority
of voriconazole to amphotericin B deoxycholate for
aspergillosis (Herbrecht et al 2002). However, the control
group may have experienced other differences in medical
management from the case group. As such, a prospective
trial which compares combination therapy versus
voriconazole monotherapy would be more telling. In
addition, a more recent study of 146 patients, 32% of whom
were solid organ transplant recipients, found that primary
combination therapy did not affect mortality or rates of
favorable response (Kubin et al 2006).
Micafungin
A recent study of 98 bone marrow transplant recipients with
invasive aspergillosis shows similar findings with
micafungin-containing combination therapy. Initial dosing
of micafungin was 75 mg/day, with escalation to a mean
dose of 105 ± 60 mg/day. Response (complete and partial)
was seen in 25/98 (26%) patients, the majority (83) of whom
were refractory to previous therapy (Kontoyiannis et al
2006).
Micafungin combination therapy has also been evaluated
in a case series involving 6 patients with pulmonary
aspergillosis (2 with probable infection). Patients received
intravenous amphotericin B deoxycholate (0.8–1.5 mg/kg/
day) and micafungin (150–300 mg daily) for 14–90 days.
4/6 patients showed response in both radiological and
mycological studies. 5/6 were determined to have treatment
success (determined by the occurrence of one or more of
the following without deterioration in any criteria: complete
or partial response in clinical symptoms, radiological
findings, and mycological tests) (Miyazaki et al 2005).
Summary
To our knowledge, only one randomized clinical trial has
evaluated combination therapy for the treatment of fungal
infections (Rex et al 2003). In vitro and animal data are of
especially limited use in invasive fungal diseases, due to
the numerous patient-specific factors that greatly affect
patient outcomes. In addition, the available clinical studies
evaluating combination therapy are fraught with limitations
and discrepancies. New studies have not rectified these
issues, and add to a confusing mix of diverse disease states,
drug combinations, and study designs. This has made the
topic very controversial, and at this time, practice seems to
be based more on preference and theory than on evidence.
This is evidenced by the varied opinions of experts in the
field (Chamolis and Kontoyannis 2006; Munoz et al 2006;
Leather and Wingard 2006). Thus, firm recommendations
regarding the use of combination therapy can not be givenTherapeutics and Clinical Risk Management 2007:3(1) 91
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at this time. However, based on the available evidence, it
appears that the use of caspofungin in combination with
either voriconazole or amphotericin B should be considered
by clinicians in patients with Aspergillus infections
refractory to single-agent therapy, or those with disseminated
disease. This benefit, although not certain at this point, is
logical, when one considers the mechanisms of action of
the different antifungal agents, as well as caspofungin’s
proven efficacy in refractory aspergillosis. At this time,
micafungin has shown similar trends in one trial and a case
series, while anidulafungin has only been tested in vitro
models. The evidence concerning combination therapy in
infections due to other fungi is too limited to extrapolate
clinically.
Dosage/administration
The dosages for the treatment of FDA-approved indications
in adults are listed in Table 4. For all echinocandins, slow
infusions (1 hour for caspofungin and micafungin, a rate
≤1 mg/minute for anidulafungin) are recommended.
Pharmacokinetic data support the use of once daily
intravenous dosages for all echinocandins. Micafungin is
the sole echinocandin for which a loading dose is not
recommended. In addition, optimal dosages of micafungin
have not been established in either esophageal or systemic
infections. Thus far, dosages for the treatment of esophageal
candidiasis in HIV-infected patients have ranged from 50 mg
to 150 mg daily, while dosages of up to 300 mg daily have
been utilized for the treatment of invasive aspergillosis.
For all echinocandins, dosage adjustments are not
required based on race, for the elderly, or for patients with
severe renal dysfunction. Anidulafungin does not require
any dose adjustment in patients with severe hepatic
dysfunction, and micafungin does not require dosage
adjustment in moderate dysfunction (has not been studied
in severe dysfunction). The caspofungin maintenance dose,
however, should be reduced to 35 mg daily in patients with
moderate to severe hepatic dysfunction.
Availability
As of April 2006, caspofungin, micafungin, and
anidulafungin are all FDA-approved in the US (Table 5).
Caspofungin and micafungin are also available in Japan and
Europe.
Summary
The echinocandins are important and exciting agents
because of their novel mechanism of action, low incidence
of serious adverse effects, and low potential for drug–drug
interactions. As a class, they demonstrate potent activity
against Candida spp., and are an option for the treatment of
infections due to these organisms. In addition, caspofungin
is a viable option for the treatment of refractory aspergillosis.
Although micafungin is not FDA-approved for this
indication, recent data suggests that it may also be effective.
Likewise, caspofungin- or micafungin-containing
combination therapy should be a considereation for the
Table 4 Adult dosing of echinocandins (Krause, Reinhardt, et al 2004; Cancidas PI 2005; Mycamine PI 2005; Reboli et al 2005;
Ruhnke et al 2005; Eraxis PI 2006)
Indication Dosage
Caspofungin Micafungin Anidulafungin
(Cancidas
®) (Mycamine
®) (Eraxis
®)
FDA approval (year) January 2001 March 2005 February 2006
Empirical therapy for presumed fungal infections in 70 mg LD - -
febrile, neutropenic patients 50 mg daily MD
Treatment of candidemia and the following 70 mg LD 100 mg daily MD* 200 mg LD100 mg daily MD
Candida infections: intra-abdominal abscesses, 50 mg daily MD
peritonitis, and pleural space infections
Treatment of invasive aspergillosis in patients who 70 mg LD - -
are refractory to or intolerant of other therapies 50 mg daily MD
Treatment of patients with esophageal candidiasis 50 mg daily MD 150 mg daily MD 100 mg LD50 mg daily MD
Prophylaxis of Candida infections in patients - 50 mg daily MD -
undergoing HSCT
Note: *dosage used in clinical trial, however, not an FDA-approved dosage or indication
Abbreviations: FDA, Food and Drug Administration; LD, loading dose; MD, maintenance dose; HSCT, hematopoietic stem cell transplantation.Therapeutics and Clinical Risk Management 2007:3(1) 92
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treatment of severe infections due to Aspergillus spp..
Although the echinocandins share many common properties,
data regarding their differences are emerging at a rapid pace.
However, there continues to be a dire need for additional
data concerning the echinocandins. Specifically, head-to-
head comparison trials would help delineate differences
between in vitro (theory) and in vivo clinical practice. More
data are needed concerning echinocandin use as initial
therapy for invasive aspergillosis. In addition, considering
the substantial cost and somewhat theoretical benefit of
combination therapy, controlled trials analyzing this use of
echinocandins are desperately needed. Finally, continued
data regarding the use of echinocandins for the treatment of
unusual infections (meningitis, endopthalmitis, endocarditis,
etc) would also help clarify the echinocandins’ place in the
antifungal armamentarium.
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